Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Telix Pharmaceuticals ( (AU:TLX) ) has provided an update.
Telix Pharmaceuticals Limited announced the cessation of Harry Kevin McCann as a director effective May 21, 2025. McCann held indirect interests in the company through Monjoy Pty Limited and Cottesloe Pty Limited, with a total of 1,120,000 fully paid ordinary shares. This change in the board may impact the company’s governance structure and could have implications for its strategic direction.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$26.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals Limited operates in the biotechnology sector, focusing on developing diagnostic and therapeutic products for cancer and rare diseases. The company is known for its innovative approach in the field of molecularly targeted radiation therapy, aiming to improve patient outcomes in oncology.
Average Trading Volume: 1,953,939
Technical Sentiment Signal: Buy
Current Market Cap: A$8.7B
Find detailed analytics on TLX stock on TipRanks’ Stock Analysis page.